Publicaciones en colaboración con investigadores/as de Christie Hospital NHS Foundation Trust (10)

2022

  1. Code of practice needed for samples donated by trial participants

    The Lancet Oncology

2021

  1. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study

    European Journal of Cancer, Vol. 151, pp. 49-62

2017

  1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2014

  1. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis

    Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039

2013

  1. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial

    The Lancet Oncology, Vol. 14, Núm. 1, pp. 72-80

  2. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

    Critical Reviews in Oncology/Hematology, Vol. 85, Núm. 3, pp. 315-331

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177

2005

  1. Adjuvant docetaxel for node-positive breast cancer

    New England Journal of Medicine, Vol. 352, Núm. 22, pp. 2302-2313

  2. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    Annals of Oncology, Vol. 16, Núm. 10, pp. 1569-1583